Read the current Defeat Diabetes® E-Lerts™ Newsletter

This website is certified by Health On the Net Foundation. Click to verify.
This site complies with the HONcode standard for trustworthy health information:
verify here.

 
 
 
     
    
      
       
Defeat Diabetes
Foundation
150 153rd Ave,
Suite 300

Madeira Beach, FL 33708
  

Drugs » Exenatide

Search our News Articles Archives for diabetes and health news. Search by word or phrase.  The latest article will appear first.

Search For:  

Search in all categories / subcategories
Search in current category / subcategory

EASD: Once a Year Exenatide Introduced at EASD
Posted: Monday, October 08, 2012
Continuous long-term delivery of exenatide with Intarcia's osmotic mini-pump system allows optimal dose selection for improved glycemic control, ensures adherence, and improves patient tolerability.

A Systematic Review of Newer Drugs for Glucose Control
Posted: Sunday, February 06, 2011
The National Institute for Health and Clinical Excellence (NICE) issued an updated Guideline for newer drugs for the management of all aspects of Type 2 diabetes. The guidelines review the newer agents from four classes with a cost analysis.

For Those 60 Percent of Type 2 Patients Who Are Not in Control
Posted: Saturday, January 29, 2011
Consider a GLP-1 plus a long-acting insulin.

Combining Exenatide with Insulin May Be 'Best Result Ever' for Diabetes Patients
Posted: Tuesday, December 21, 2010
Combining the newer diabetes drug exenatide with insulin provides better blood sugar control in patients with Type 2 diabetes than insulin alone and helps promote weight loss.

A Once-A-Year Continuous Exenatide Therapy Shows 100% Compliance
Posted: Sunday, October 10, 2010
Implantable device promises diabetes patients continuous exenatide therapy with 100% compliance. Tolerability and weight loss was better with ITCA 650 20 μg/day than with exenatide injections.

EASD: Once-Weekly Exenatide Benefit Sustained over 52 Weeks
Posted: Sunday, October 03, 2010
Once-Weekly Exenatide maintains a drop in A1c of 2 points for more than 52 weeks.

Transdermal GLP-1 Patch for Type 2 Diabetes
Posted: Wednesday, September 29, 2010
TransPharma Medical, Ltd., announced the successful completion of a Phase 1a trial of ViaDerm-GLP1 agonist which is being developed for the treatment of Type 2 diabetes.

Switching to Once-Daily Victoza(R) (Liraglutide) from Exenatide Further Improves Blood Sugar Control in Patients with Type 2 Diabetes
Posted: Sunday, April 04, 2010
Diabetes Care has published online the results of the Novo Nordisk (NVO) LEAD™ 6 extension study...

Special Newsflash: Exenatide Once Weekly -- FDA Update
Posted: Tuesday, March 16, 2010
Amylin, Lilly and Alkermes received a Complete Response Letter from FDA for Exenatide Once Weekly. New drug to be called BYDUREON (exenatide for extended-release injectable suspension).

In the complete response letter there are no requests for new pre-clinical or clinical trials. Requests raised in the letter primarily relate to the finalization of the product labeling with accompanying Risk Evaluation and Mitigation Strategy (REMS) and clarification of existing manufacturing processes.

Exenatide Once Weekly DURATION-5 Study Results Announced
Posted: Sunday, December 20, 2009
Eli Lilly and Company, and Amylin announced positive results from a head-to-head study comparing exenatide once weekly, an investigational diabetes therapy, to BYETTA® (exenatide) injection taken twice daily, in patients with Type 2 diabetes.

Page 1 of 2
1  |  2

 
 
 
 
 
Join us on Facebook
 
 
 

Send your unopened, unexpired diabetes testing supplies to:

Defeat Diabetes Foundation
150 153rd Ave, Suite 300
Madeira Beach, FL 33708

 

DDF advertisement
 

 Friendly Banner
 


Friendly Banner
 
 
 
Analyze nutrition content by portion
DDF advertisement